Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600X |
Therapy | Vemurafenib |
Indication/Tumor Type | Erdheim-Chester disease |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600X | Erdheim-Chester disease | sensitive | Vemurafenib | FDA approved | Actionable | In a Phase II trial (VE-BASKET) that supported FDA approval, Zelboraf (vemurafenib) treatment resulted in an objective response rate of 54.5% (12/22, 1 complete and 11 partial responses) in patients with Erdheim-Chester disease harboring BRAF V600 mutations, with a 2-year progression-free survival rate of 83% and 2-year overall survival rate of 95% (PMID: 29188284; NCT01524978). | detail... 29188284 |
PubMed Id | Reference Title | Details |
---|---|---|
Zelboraf (vemurafenib) FDA Drug Label | Full reference... | |
(29188284) | Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. | Full reference... |